VIR-5500
-
VIR-5500: Promising Phase 1 Update for Metastatic Prostate Cancer Patients
Vir Biotechnology’s VIR-5500, a novel T-cell engager for advanced prostate cancer, showed promising safety and anti-tumor activity in Phase 1 trials. The therapy demonstrated significant PSA declines and objective responses in heavily pre-treated patients, with manageable side effects. This dual-targeting approach, utilizing PRO-XTEN® masking, aims for a differentiated therapeutic index, potentially offering a new option for patients with limited treatment choices.
